SLC20A1 is a prospective prognostic and therapy response predictive biomarker in head and neck squamous cell carcinoma
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.High SLC20A1 expression is linked to poor prognosis in head and neck squamous cell carcinoma (HNSCC). This finding suggests SLC20A1 may serve as a crucial prognostic biomarker and therapeutic indicator in HNSCC patients.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Research
Background
- Solute carrier family 20 member 1 (SLC20A1) is a known cancer biomarker but its predictive role in head and neck squamous cell carcinoma (HNSCC) remains understudied.
- Understanding SLC20A1's function in HNSCC is crucial for developing new diagnostic and therapeutic strategies.
Purpose Of The Study
- To investigate the prognostic significance of SLC20A1 in HNSCC.
- To explore the association between SLC20A1 expression and clinical characteristics, patient survival, and biological pathways in HNSCC.
Main Methods
- Analysis of SLC20A1 expression (mRNA and protein) in HNSCC tissues using TCGA, qRT-PCR, and Western blot.
- Assessment of cellular behaviors (invasion, migration, proliferation) via Transwell, wound healing, and colony formation assays.
- Exploration of associated biological pathways and immune microenvironment using GO, KEGG, GSEA, and TIMER/CIBERSORT databases.
Main Results
- SLC20A1 mRNA and protein expression were significantly elevated in HNSCC tissues compared to normal tissues.
- High SLC20A1 expression correlated with advanced T stage, increased risk scores, and reduced overall survival in HNSCC patients.
- SLC20A1 emerged as an independent predictive factor for HNSCC prognosis, alongside stage and age.
Conclusions
- Overexpression of SLC20A1 in HNSCC is associated with increased cellular invasion, migration, and proliferation, indicating a poor prognosis.
- SLC20A1 serves as a potential prognostic biomarker and a predictive indicator for therapeutic response in HNSCC.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...